Parabilis Medicines Sets Terms for a $476M Nasdaq IPO — What the Helicon Peptide Platform Means for Oncology Research

Key takeaways

• Parabilis Medicines (formerly FogPharma) set IPO terms on 4 June 2026, targeting up to $476M on Nasdaq under the ticker PBLS, with pricing expected during the week of 9 June 2026.
• The offering follows a May 2026 collaboration with Regeneron worth $125M upfront and near-term plus up to $2.2B in potential milestones, centred on a novel Antibody-Helicon Conjugate (AHC) format.
• Lead asset zolucatetide — a Helicon stabilised helical peptide — recorded a 100% disease-control rate and a 74% objective response rate in response-evaluable desmoid tumour patients in Phase 1/2, with Phase 3 initiation planned for H1 2027.
• The Helicon modality is designed to engage flat, intracellular protein surfaces inaccessible to conventional small molecules or antibodies, addressing a long-standing structural barrier in drug discovery.
• For UK research-procurement teams, Parabilis represents the largest pure-play engineered-peptide IPO attempt to date in 2026, signalling continued institutional appetite for non-GLP-1 peptide platforms.

What is Parabilis Medicines and what is the Helicon platform?

Cambridge, Massachusetts-based Parabilis Medicines — rebranded from FogPharma, which was founded in 2015 — is a clinical-stage biotech built around a proprietary class of therapeutics it calls Helicons. According to Parabilis' SEC filing, Helicons are "stabilised helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines." The company's thesis is that the α-helical secondary structure of these peptides allows them to engage the flat, extended protein–protein interaction surfaces that are notoriously difficult for small molecules to address and remain inaccessible to biologics because they are intracellular.

Parabilis describes its Helicon platform as combining "the precision of antibodies with the intracellular access and tunability of small molecules to reach historically undruggable targets." The approach positions Helicons between the two dominant modalities in modern pharmacology — neither a conventional small molecule nor a biologic — which is a structural distinction that has attracted sustained interest from research teams working on transcription factor biology.

The lead asset: zolucatetide and the Wnt/β-catenin pathway

Zolucatetide (formerly FOG-001) is the first drug candidate to directly inhibit the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors. According to Parabilis, this is "the central node in the Wnt/β-catenin cell signalling pathway, which regulates cell proliferation and differentiation and whose hyperactivation is a driver of millions of cancer cases annually." The company states that targeting this node had "eluded three decades of intensive efforts" across the industry prior to zolucatetide's development.

The Wnt/β-catenin pathway is estimated to be dysregulated in more than 10% of all cancers, making it a high-value target if it can be reliably inhibited. Desmoid tumours — rare, locally aggressive, non-metastatic growths arising in connective tissue — are among the cleanest single-driver indications because β-catenin mutations are the primary disease mechanism, making them a logical first clinical proof-of-concept target.

Clinical data: Phase 1/2 results

As of February 2026, 38 patients had been enrolled and treated with zolucatetide in the ongoing Phase 1/2 desmoid tumour trial (NCT05919264). Of the 25 patients with sufficient follow-up to be response-evaluable, all 25 demonstrated tumour reductions — a 100% disease-control rate — and 14 of the 19 patients with at least two post-baseline scans achieved an objective response per RECIST 1.1 criteria, equating to a 74% objective response rate.

The FDA has granted zolucatetide both Orphan Drug and Fast Track designations for desmoid tumours, with the Orphan Drug designation confirmed in March 2026. More than 150 patients have been dosed to date across the Phase 1/2 programme, and the company has indicated it will share further data readouts across 2026.

Beyond desmoid tumours, early clinical data have been presented for zolucatetide in familial adenomatous polyposis (FAP), hepatocellular carcinoma (HCC), adamantinomatous craniopharyngioma (ACP), and several additional Wnt-driven tumour types. The programme is designed to test the hypothesis that β-catenin:TCF inhibition can serve as a backbone across a spectrum of genetically simple and biologically complex cancers.

The Regeneron deal and the AHC concept

In May 2026, Parabilis announced a strategic collaboration with Regeneron Pharmaceuticals. According to the company's press release, the agreement provides for Parabilis to receive $125M from Regeneron — comprising a $50M upfront payment and a $75M equity commitment — with up to approximately $2.2B in additional potential milestone payments plus tiered royalties.

The collaboration centres on Antibody-Helicon Conjugates (AHCs): a format that would couple Regeneron's antibody targeting capabilities to Helicon payloads. The rationale, per Parabilis's filing, is to use antibodies to direct Helicons to specific cells, with the Helicon then modulating an intracellular protein target once inside. The concept is structurally analogous to antibody-drug conjugates (ADCs), but replaces a cytotoxic payload with a conformationally specific peptide designed to disrupt a protein–protein interaction. Parabilis frames the arrangement as "a capital-efficient approach to explore the broader applicability of Helicons."

The IPO: terms, use of proceeds, and financial context

According to a 4 June 2026 SEC filing, Parabilis aims to sell 25 million shares at $17 to $19 per share. At the $18 midpoint, the company expects to raise approximately $413M in the base offering, rising to $476M if underwriters exercise overallotment options in full. The company intends to list on Nasdaq under the ticker PBLS, with pricing expected the week of 9 June 2026. Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital are joint bookrunners.

Parabilis has raised more than $800M in private funding since its founding, most recently through a $305M Series F in January 2026. As of 31 March 2026, the company held $329M in cash and equivalents. Proceeds from the IPO are allocated as follows: approximately $150M for zolucatetide in desmoid tumours (including Phase 3 initiation), $120M for zolucatetide across additional indications, $130M for broader pipeline advancement, and the remainder for platform development and general corporate purposes. The company expects these funds to support operations into the second half of 2029.

In 2026, biotech IPOs are averaging more than $286M in total proceeds across 11 completed offerings, suggesting Parabilis is targeting the upper tier of the current market window.

What this means for research-procurement teams

The Parabilis IPO is notable for UK and European research labs for several reasons:

A new chemical category in clinical development. Helicons occupy a distinct position in the modality landscape — they are peptide-based but stabilised against the conformational instability that limits many helical sequences in solution. Research teams working on protein–protein interaction (PPI) biology, particularly in the Wnt and transcription-factor space, may find zolucatetide's clinical progress informative for assessing assay targets and tool compound priorities.

Validation of non-GLP-1 peptide investment. Much of the 2025–2026 capital flow into peptides has been directed at GLP-1 receptor agonists and metabolic disease. Parabilis follows a Novartis deal with Unnatural Products and a Novo Nordisk partnership with Vivtex as evidence that large-scale oncology-focused peptide platforms can also attract top-tier pharma partnerships. This diversification of the investment base has implications for the reagent and tool-compound market, which often lags deal activity by 12 to 24 months.

AHC format as a research tool. The AHC concept — delivering a peptide payload via an antibody — raises practical questions about intracellular delivery, linker chemistry, and peptide stability that are directly relevant to labs developing conjugated peptide research tools. Published preclinical data from this programme, expected over the coming year, will merit close attention.

Phase 3 timeline. A global registrational Phase 3 trial in desmoid tumours is planned for H1 2027. Labs sourcing Wnt pathway tool compounds or evaluating β-catenin:TCF inhibition assay systems would be advised to monitor Parabilis's forthcoming data readouts, which the company has indicated will be released across 2026.

Regulatory designations and clinical data cited in this article are drawn from Parabilis Medicines' SEC filings and official press releases. IPO pricing was not finalised as of the date of publication.